BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Scartozzi M, Bittoni A, Pistelli M, Galizia E, Berardi R, Giampieri R, Faloppi L, Cascinu S. Toward molecularly selected chemotherapy for advanced gastric cancer: state of the art and future perspectives. Cancer Treat Rev 2009;35:451-62. [PMID: 19467788 DOI: 10.1016/j.ctrv.2009.04.008] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 1.7] [Reference Citation Analysis]
Number Citing Articles
1 Tsujimoto H, Ono S, Ichikura T, Matsumoto Y, Yamamoto J, Hase K. Roles of inflammatory cytokines in the progression of gastric cancer: friends or foes? Gastric Cancer 2010;13:212-21. [PMID: 21128056 DOI: 10.1007/s10120-010-0568-x] [Cited by in Crossref: 47] [Cited by in F6Publishing: 50] [Article Influence: 4.3] [Reference Citation Analysis]
2 Huang J, Bai Y, Huo L, Xiao J, Fan X, Yang Z, Chen H, Yang Z. Upregulation of a disintegrin and metalloprotease 8 is associated with progression and prognosis of patients with gastric cancer. Transl Res 2015;166:602-13. [PMID: 26024798 DOI: 10.1016/j.trsl.2015.05.001] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
3 Braunschmid T, Kührer I, Mittlböck M, Westerhoff M, Kappel-Latif S, Brammen L, Krishnadath KK, Phillips WA, Gnant M, Kandioler D. TP53 is not a prognostic marker-clinical consequences of a generally disregarded fact. Ann N Y Acad Sci 2018;1434:46-53. [PMID: 30112858 DOI: 10.1111/nyas.13947] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
4 Ma J, Hu X, Li J, Wu D, Lan Q, Wang Q, Tian S, Dong W. Enhancing conventional chemotherapy drug cisplatin-induced anti-tumor effects on human gastric cancer cells both in vitro and in vivo by Thymoquinone targeting PTEN gene. Oncotarget. 2017;8:85926-85939. [PMID: 29156767 DOI: 10.18632/oncotarget.20721] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 4.3] [Reference Citation Analysis]
5 Yan H, Xiao F, Zou J, Qiu C, Sun W, Gu M, Zhang L. NR4A1-induced increase in the sensitivity of a human gastric cancer line to TNFα-mediated apoptosis is associated with the inhibition of JNK/Parkin-dependent mitophagy. Int J Oncol 2018;52:367-78. [PMID: 29207128 DOI: 10.3892/ijo.2017.4216] [Cited by in Crossref: 6] [Cited by in F6Publishing: 16] [Article Influence: 1.5] [Reference Citation Analysis]
6 Konstantoudakis G, Florou D, Mavridis K, Papadopoulos IN, Scorilas A. Kallikrein-related peptidase 13 (KLK13) gene expressional status contributes significantly in the prognosis of primary gastric carcinomas. Clin Biochem. 2010;43:1205-1211. [PMID: 20678496 DOI: 10.1016/j.clinbiochem.2010.07.016] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 1.5] [Reference Citation Analysis]
7 Buhrmann C, Kunnumakkara AB, Popper B, Majeed M, Aggarwal BB, Shakibaei M. Calebin A Potentiates the Effect of 5-FU and TNF-β (Lymphotoxin α) against Human Colorectal Cancer Cells: Potential Role of NF-κB. Int J Mol Sci 2020;21:E2393. [PMID: 32244288 DOI: 10.3390/ijms21072393] [Cited by in Crossref: 17] [Cited by in F6Publishing: 11] [Article Influence: 17.0] [Reference Citation Analysis]
8 Tsujimoto H, Ono S, Ichikura T, Matsumoto Y, Yamamoto J, Hase K. Roles of inflammatory cytokines in the progression of gastric cancer: friends or foes? Gastric Cancer. 2010;13:212-221. [PMID: 21128056 DOI: 10.1007/s10120-010-0568-x.] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
9 Ding X, Zhu F, Yang Y, Li M. Purification, antitumor activity in vitro of steroidal glycoalkaloids from black nightshade (Solanum nigrum L.). Food Chemistry 2013;141:1181-6. [DOI: 10.1016/j.foodchem.2013.03.062] [Cited by in Crossref: 53] [Cited by in F6Publishing: 39] [Article Influence: 6.6] [Reference Citation Analysis]
10 Keefe DMK, Bateman EH. Tumor control versus adverse events with targeted anticancer therapies. Nat Rev Clin Oncol 2012;9:98-109. [DOI: 10.1038/nrclinonc.2011.192] [Cited by in Crossref: 65] [Cited by in F6Publishing: 53] [Article Influence: 6.5] [Reference Citation Analysis]
11 Moiseyenko VM, Volkov NM, Suspistin EN, Yanus GA, Iyevleva AG, Kuligina ESh, Togo AV, Kornilov AV, Ivantsov AO, Imyanitov EN. Evidence for predictive role of BRCA1 and bTUBIII in gastric cancer. Med Oncol. 2013;30:545. [PMID: 23532817 DOI: 10.1007/s12032-013-0545-4] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 2.0] [Reference Citation Analysis]
12 Campbell JM, Stephenson MD, Bateman E, Peters MDJ, Keefe DM, Bowen JM. Irinotecan-induced toxicity pharmacogenetics: an umbrella review of systematic reviews and meta-analyses. Pharmacogenomics J 2017;17:21-8. [DOI: 10.1038/tpj.2016.58] [Cited by in Crossref: 30] [Cited by in F6Publishing: 30] [Article Influence: 6.0] [Reference Citation Analysis]
13 Lei X, Lv X, Liu M, Yang Z, Ji M, Guo X, Dong W. Thymoquinone inhibits growth and augments 5-fluorouracil-induced apoptosis in gastric cancer cells both in vitro and in vivo. Biochem Biophys Res Commun. 2012;417:864-868. [PMID: 22206670 DOI: 10.1016/j.bbrc.2011.12.063] [Cited by in Crossref: 62] [Cited by in F6Publishing: 57] [Article Influence: 6.2] [Reference Citation Analysis]
14 Mehta S, Shelling A, Muthukaruppan A, Lasham A, Blenkiron C, Laking G, Print C. Predictive and prognostic molecular markers for cancer medicine. Ther Adv Med Oncol. 2010;2:125-148. [PMID: 21789130 DOI: 10.1177/1758834009360519] [Cited by in Crossref: 114] [Cited by in F6Publishing: 102] [Article Influence: 11.4] [Reference Citation Analysis]
15 Fornaro L, Lucchesi M, Caparello C, Vasile E, Caponi S, Ginocchi L, Masi G, Falcone A. Anti-HER agents in gastric cancer: from bench to bedside. Nat Rev Gastroenterol Hepatol. 2011;8:369-383. [PMID: 21647199 DOI: 10.1038/nrgastro.2011.81] [Cited by in Crossref: 46] [Cited by in F6Publishing: 53] [Article Influence: 4.6] [Reference Citation Analysis]
16 Bittoni A, Scartozzi M, Giampieri R, Faloppi L, Bianconi M, Mandolesi A, Del Prete M, Pistelli M, Cecchini L, Bearzi I, Cascinu S. Clinical evidence for three distinct gastric cancer subtypes: time for a new approach. PLoS One 2013;8:e78544. [PMID: 24265697 DOI: 10.1371/journal.pone.0078544] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
17 Li Y, Gong J, Zhang Q, Lu Z, Gao J, Li Y, Cao Y, Shen L. Dynamic monitoring of circulating tumour cells to evaluate therapeutic efficacy in advanced gastric cancer. Br J Cancer. 2016;114:138-145. [PMID: 26784122 DOI: 10.1038/bjc.2015.417] [Cited by in Crossref: 50] [Cited by in F6Publishing: 49] [Article Influence: 10.0] [Reference Citation Analysis]
18 Gubanski M, Glimelius B, Lind PA. Quality of life in patients with advanced gastric cancer sequentially treated with docetaxel and irinotecan with 5-fluorouracil and folinic acid (leucovin). Med Oncol 2014;31:906. [PMID: 24627237 DOI: 10.1007/s12032-014-0906-7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
19 Fornaro L, Lucchesi M, Caparello C, Vasile E, Caponi S, Ginocchi L, Masi G, Falcone A. Anti-HER agents in gastric cancer: from bench to bedside. Nat Rev Gastroenterol Hepatol. 2011;8:369-383. [PMID: 21647199 DOI: 10.1038/nrgastro.2011.81.] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
20 Liu X, Yu H, Cai H, Wang Y. The expression and clinical significance of miR-132 in gastric cancer patients. Diagn Pathol. 2014;9:57. [PMID: 24621117 DOI: 10.1186/1746-1596-9-57] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 3.9] [Reference Citation Analysis]
21 Refolo MG, Lotesoriere C, Lolli IR, Messa C, D'Alessandro R. Molecular mechanisms of synergistic action of Ramucirumab and Paclitaxel in Gastric Cancers cell lines. Sci Rep 2020;10:7162. [PMID: 32346056 DOI: 10.1038/s41598-020-64195-x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]